Cellumed셀루메드
049180 · KOSDAQ · ₩049180 · 셀루메드
- Market cap
- ₩84B
- Enterprise value
- ₩88B
- P/E
- 31.4×
- P/B
- 3.3×
- Dividend yield
- 0.0%
- ROE
- 10.5%
- Net margin
- 2.2%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−66.1% from the high
₩650Today: ₩1,009 – ₩1,009₩2,975
Returns
- 1W0.0%
- 1M0.0%
- 3M0.0%
- 6M0.0%
- YTD−12.6%
- 1Y+47.1%
- Volume today
- —
- Traded today
- —
- Listed shares
- 83,226,192
- EPS (12 months)
- ₩32
- Earnings yield 3.2%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
- MomentumFlat0% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Cellumed stock overview
Cellumed (셀루메드, KRX: 049180) is listed on KOSDAQ, in the Biotech & Pharma sector. , Ltd. Its shares closed at ₩1,009 on Oct 29, 2026, unchanged on the day, giving it a market value of ₩84B.
Key facts
- Market cap
- ₩84B
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 29, 2026
- Main business
- , Ltd.
Quick answers about Cellumed
- What does Cellumed do?
- , Ltd. is a Korean company that operates in medical devices, biologics, and cosmeceuticals, and it also has subsidiaries in environmental facility construction, general facility construction, and real estate development. Its medical device products include tissue-engineered bone grafts, artificial knee joints, and allografts sourced from donors, and its biologics business manufactures and distributes recombinant bone growth factor (rhBMP2) grafts and a synovial fluid substitute.
- What is the market cap of Cellumed?
- The market capitalisation of Cellumed was ₩84B at the close on Oct 29, 2026.
- Who are the largest shareholders of Cellumed?
- According to the latest official filings, the largest reported holders are TD Landmark Fund No. 1 (33.91%, as of Jan 28, 2026); Pretty (11.05%, as of Mar 19, 2026); Sangsangin Savings Bank (2.29%, as of Aug 25, 2025).
- When is the next earnings report from Cellumed?
- Korean companies rarely announce results dates in advance. Based on when Cellumed filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
Company profile
Cellumed Co., Ltd. is a Korean company that operates in medical devices, biologics, and cosmeceuticals, and it also has subsidiaries in environmental facility construction, general facility construction, and real estate development. Its medical device products include tissue-engineered bone grafts, artificial knee joints, and allografts sourced from donors, and its biologics business manufactures and distributes recombinant bone growth factor (rhBMP2) grafts and a synovial fluid substitute. Its cosmeceutical line uses the growth factor FGF7 in skin-care ingredients. Most of its 2025 revenue came from the construction and equipment segment, which includes environmental facility and general facility projects, and the company reports selling its products in overseas markets such as Taiwan, Thailand, and the United States.
Written by AI from the company's latest annual report.
- Korean name
- 셀루메드
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 유인수
- Founded
- Apr 1985
- Listed
- May 2002
- Listed shares
- 83,226,192
- Fiscal year ends
- Month 12
- Website
- www.cellumed.co.kr
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- Yuhan000100 · ₩5.5T₩74,700−3.36%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
Recent filings
See all- Amended: Shareholders' meeting calledOct 13, 2026
- [Amended] Notice of Shareholder Register Closure Period or Record Date SettingOct 13, 2026
- Amended: Half-year report (Jun 2026)Oct 13, 2026
- Amended: Shareholders' meeting calledSep 23, 2026
- Amended: Shareholders' meeting calledAug 27, 2026
Titles in Korean until English translations are added.
Also known as: Cellumed / 셀루메드 / 049180 / KRX:049180
Source: KRX statistical information